This article was first published in the Fall 2020 issue of Critical Connections. The most common uses for neuromuscular blocking agents (NMBAs) in the intensive care unit (ICU) are in the treatment of acute respiratory distress syndrome (ARDS), status asthmaticus, rapid sequence intubation (RSI), and therapeutic hyperthermia. As institutions continue to care for surges of critically ill patients with COVID-19, demand for medications to support these patients has increased. This has led to a worsening drug shortage of NMBAs, particularly cisatracurium. Critical Connections is the critical care industry’s only newsmagazine, provides information on cutting-edge topics in critical care useful to the entire multiprofessional team. Authors: Joanna L. Stollings, PharmD, FCCP, FCCM Darlene Chaykosky, PharmD, BCPS, BCCCP Ryan Hakimi, DO, MS, FNCS, NVSJoanna L.Stollings, PharmD, FCCP, FCCM; Darlene Chaykesky, PharmD, BCPS, BCCCP; Ryan Hakimi, DO, MS, FNCS, NVS